Interim Report April - June 2025
Regulatory
A strong start to the year - Sales and operating profit growing, good progress in business development
Press Releases
Invitation to presentation in connection with EQL Pharma's interim report, first quarter, 2025/26
EQL Pharma AB (publ) will publish its interim report for the first quarter, 2025/26, on Friday, August 8[th], before stock markets open.
Notice of annual general meeting in EQL Pharma AB
Regulatory
The shareholders of EQL Pharma AB, Reg. No. 556713-3425, are hereby invited to the annual general meeting to be held on Thursday 21 August 2025 at 16.00 at the company’s premises at Stortorget 1 in...
EQL takes first step to establish itself in Germany and the Netherlands
EQL has now taken the first step to establish itself in Germany and the Netherlands by recruiting key people with knowledge of the local markets who can identify, develop/in-license and launch nich...
Memprex© (methenamine hippurate) license signed with partner for BeNeLux
EQL's key product Memprex[©] has now been licensed for sale in BeNeLux (Belgium, Netherlands, Luxemburg) with Goodlife Specialty BV, a leading local pharmaceutical company specialising in women’s h...